- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Myriad and UHC Sign a 3-year Contract for the myRisk Hereditary Cancer Test
The molecular diagnostic testing company Myriad Genetics announced that it had signed a 3-year contract with UnitedHealthcare to make their myRisk cancer susceptibility test accessible to patients.
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and the myRisk Hereditary Cancer test for patients who meet the hereditary cancer testing eligibility criteria.
Myriad's myRisk Hereditary Cancer test uses next-generation sequencing technology to evaluate 25 clinically significant hereditary cancer genes associated with eight major hereditary cancers including: breast, colon, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma. The myRisk test has demonstrated in multiple clinical studies a significant increase in sensitivity by identifying over 50 percent more patients with deleterious mutations that place a patient at substantially greater lifetime risk for cancer.
"Myriad has been a pioneer in hereditary cancer testing for almost 20 years," said Mark Capone, president of Myriad Genetic Laboratories. "Through scientific research and innovation, Myriad is able to provide a significantly more comprehensive, next generation cancer test for hereditary cancer syndromes.
Source: Myriad Genetics
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
